Carlsmed, Inc. (NASDAQ:CARL) Receives Average Recommendation of “Hold” from Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have been given an average rating of “Hold” by the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $21.3333.

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (e-)” rating on shares of Carlsmed in a research note on Monday, December 22nd. The Goldman Sachs Group reissued a “buy” rating and issued a $20.00 price objective on shares of Carlsmed in a report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and set a $24.00 target price on shares of Carlsmed in a report on Monday, December 15th. Truist Financial reiterated a “buy” rating and issued a $20.00 price target (up from $18.00) on shares of Carlsmed in a report on Friday, November 7th. Finally, Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th.

Carlsmed Stock Down 1.2%

CARL stock opened at $13.21 on Friday. The firm has a market cap of $353.10 million and a PE ratio of -3.61. Carlsmed has a 52 week low of $10.65 and a 52 week high of $17.19. The company has a quick ratio of 8.74, a current ratio of 8.87 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average of $12.68.

Carlsmed (NASDAQ:CARL) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Carlsmed had a negative net margin of 58.67% and a negative return on equity of 72.60%. The business had revenue of $15.16 million during the quarter, compared to analysts’ expectations of $15.20 million.

Institutional Investors Weigh In On Carlsmed

Hedge funds have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC raised its stake in shares of Carlsmed by 6.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 15,800 shares of the company’s stock valued at $195,000 after buying an additional 1,000 shares during the last quarter. Barclays PLC grew its holdings in Carlsmed by 10.6% during the fourth quarter. Barclays PLC now owns 10,633 shares of the company’s stock worth $131,000 after acquiring an additional 1,021 shares during the period. Russell Investments Group Ltd. raised its position in Carlsmed by 0.8% during the fourth quarter. Russell Investments Group Ltd. now owns 160,238 shares of the company’s stock valued at $1,979,000 after acquiring an additional 1,292 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Carlsmed in the third quarter valued at approximately $33,000. Finally, JPMorgan Chase & Co. purchased a new stake in Carlsmed in the 3rd quarter worth approximately $37,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).